New drugs in psychiatry - cariprazine, lurasidone, esketamine
Introduction: Invariably, the search for an “ideal drug” in psychiatry has been going for years, one that is safe and effective, prevents relapse and shows the least possible side effects.
Enregistré dans:
Auteurs principaux: | Pożarowska Kinga, Rusinek Adam, Rudziński Gracjan, Soroka Ewelina, Masiak Jolanta |
---|---|
Format: | article |
Langue: | DE EN PL UK |
Publié: |
Sciendo
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/b5a7dc5b9f6e474fa0d4b721ff2a27c1 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
par: Aleksandr M. Reznik, et autres
Publié: (2020) -
Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
par: Octavian Vasiliu
Publié: (2021) -
Escitalopram, bupropion, lurasidone, lamotrigine and possible vortioxetine overdose presented with serotonin syndrome and diffuse encephalopathy: A case report
par: Suthimon Thumtecho, et autres
Publié: (2021) -
Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
par: Borjanka Batinic, et autres
Publié: (2021) -
Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
par: Iyo M, et autres
Publié: (2021)